There has been a dearth of options available to clinicians when it comes to the pharmacological management of methamphetamine use disorder. On this background, a group from the USA have conducted a multisite, double-blind, two-stage, placebo-controlled trial with the use of a sequential parallel comparison design to evaluate the efficacy and safety of extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg per day) in adults with moderate or severe methamphetamine use disorder. Urine samples were obtained from participants twice weekly was used as a measure of outcomes, and the primary outcome was defined as at least three methamphetamine-negative urine samples out of four samples obtained at the key milestones in the study. The weighted average response across the two stages of the study was 13.6% with naltrexone–bupropion and 2.5% with placebo. Serious adverse events were uncommon. Although the response rate was low, this study at least provides an indicator that the approach offers some degree of benefit and could be further explored. See more details here.